ArticleFrontiers in oncology2025
A preoperative risk scoring system for survival prediction in clinical stage IB lung adenocarcinoma: a multicenter study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical stage (c-stage) IB lung adenocarcinoma (LUAD) presents variable survival outcomes, and the prognostic significance of factors such as ground-glass opacity components and positron emission tomography (PET) metrics remains unclear. Despite recent advances, no preoperative scoring model has been established to stratify risk in this subgroup. We aimed to identify preoperative prognostic factors in c-stage IB LUAD and develop a simple scoring system for predicting overall survival (OS). Methods: We retrospectively analyzed data from 245 patients with c-stage IB LUAD who underwent lobectomy at three institutions between 2010 and 2020. Cox regression analysis was performed to identify independent preoperative prognostic factors for OS. A risk score was developed by assigning points to each factor, based on the regression coefficients. Thereafter, patients were stratified into four risk groups based on their total scores. Results: Multivariate analysis identified smoking history (hazard ratio [HR]: 2.68; 95% confidence interval [CI]: 1.13-6.33; p=0.025), elevated serum carcinoembryonic antigen (CEA) levels (HR: 2.89; 95%CI: 1.42-5.91; p=0.004), and high maximum standardized uptake value (SUVmax) on PET (HR: 2.84; 95%CI: 1.16-6.98; p=0.023) as independent factors of poor prognosis. A scoring system was established by assigning one point to each factor. Patients were stratified into four risk groups: low (score 0, n=41), moderate (score 1, n=84), moderately high (score 2, n=77), and extremely high (score 3, n=43). Five-year OS rates were 100.0%, 89.3%, 74.0%, and 52.1%, respectively (p<0.001). The prognostic model demonstrated acceptable discrimination ability, with an area under the curve of 0.738 (95% CI, 0.661-0.815) and a concordance index of 0.753 (95% CI, 0.682-0.824). Notably, patients with a score of 0 showed low-grade tumors and favorable prognosis, whereas those with a score of 3 had more aggressive pathological characteristics and significantly worse outcomes. Conclusions: We developed and validated a simple preoperative scoring system using smoking history, serum CEA level, and tumor SUVmax to predict prognosis in c-stage IB LUAD. This model provides a practical tool for risk stratification and may support individualized treatment decisions, including the consideration of induction therapy in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.